Additionally, altered levels in MAO-A and MAO-B showed increased neurotoxic monoamine metabolites promoting Aβ deposition where MAO inhibitors (MAOIs) have also show efficacy in treating AD-related neurodegeneration via this pathway [26]. This evidence concerns the gene MAOA and Alzheimer disease.